Frequency of growth hormone deficiency in short statured children

Tariq Mahmood Awan1, Abdus Sattar, Ehsan Gul Khattak

  • 1Department of Pathology, Combined Military Hospital, Thall Cantt.

Insights

Growth hormone deficiency affects approximately 14% of short stature children in hospital settings. This study evaluated children referred for growth hormone testing using stimulation tests and insulin tolerance tests.

Area of Science:

  • Pediatric Endocrinology
  • Growth Disorders
  • Hormone Deficiency

Background:

  • Short stature is a common concern in pediatric endocrinology.
  • Accurate diagnosis of growth hormone deficiency (GHD) is crucial for appropriate treatment.
  • Evaluating the prevalence of GHD in referred populations informs clinical practice.

Purpose of the Study:

  • To determine the frequency of growth hormone deficiency (GHD) in children with short stature.
  • To assess the diagnostic utility of screening tests compared to insulin tolerance test (ITT).

Main Methods:

  • A cross-sectional survey of 293 children referred for growth hormone evaluation.
  • Clinical assessment, height, and weight measurements were recorded.
  • Screening for GHD used exercise and L-dopa stimulation tests; confirmed with insulin tolerance test (ITT).

Main Results:

  • Initial screening identified 24.17% of children with potential GHD (GH level < 10 mIU/L).
  • After ITT confirmation, the frequency of GHD was found to be 13.9%.
  • Screening tests demonstrated a positive predictive value of 70.4% and a false positivity rate of 6.8%.

Conclusions:

  • Growth hormone deficiency accounts for approximately 14% of short stature cases in this hospital setting.
  • ITT is essential for confirming GHD after initial screening.
  • Understanding GHD prevalence aids in managing pediatric short stature.
Abstract

Related Concept Videos

Polygenic Traits01:18

Polygenic Traits

When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...